Clinical Trials Center

What Clinical Trials Center does

Clinical Trials Center of Middle Tennessee (legal entity: Clinical Trials of Middle Tennessee, LLC) is a physician-led clinical research site founded in 2019 and headquartered in Franklin, Tennessee. The company operates as a community-based Phase 2 and Phase 3 trial site, executing protocols on behalf of pharmaceutical sponsors in two therapeutic verticals: pulmonary disease (asthma, COPD, bronchiectasis, idiopathic and progressive pulmonary fibrosis) and metabolic disease (obesity, Type II diabetes, including oral GLP1 therapies). Its core products are five active trial programs — Asthma, Bronchiectasis, COPD, Oral GLP1, and Pulmonary Fibrosis — each running multiple concurrent studies with sponsors including AstraZeneca, GSK, Boehringer Ingelheim, Pfizer, Merck, PureTech, Avalyn, Verona Pharma, CSL Behring, Sanofi, Chiesi, and United Therapeutics.

The company's underlying operations are structured around two co-founding Principal Investigators (Dr. Alex Slandzicki, board-certified in family medicine, CEO; and Dr. Aaron Milstone, board-certified in pulmonary, sleep, internal, and critical care medicine, President) supported by a CCRC-certified Clinical Research Director, a Family Nurse Practitioner sub-investigator, and several clinical research coordinators and assistants. Patient recruitment combines direct outreach through the company website and phone channel with physician referrals, and the site maintains coordination with participants' established physicians throughout each study.

Revenue is generated under a professional services model, with pharmaceutical sponsors paying the site per protocol for study conduct, patient enrollment, and data collection. Participation is free for patients, with study-related visits, treatments, and procedures covered by sponsors and some trials offering compensation for time and travel. The company is privately held by its physician founders with no disclosed external funding, no parent company, and operates exclusively from a single clinic location in Franklin, TN serving the Middle Tennessee market.

Name

Clinical Trials Center

Legal name

Clinical Trials of Middle Tennessee, LLC

Website

https://ctcmidtn.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

Clinical Trials Center of Middle Tennessee is a physician-led clinical research site in Franklin, TN that conducts Phase 2 and Phase 3 trials in pulmonary and metabolic diseases on behalf of major pharmaceutical sponsors, recruiting patients from the Middle Tennessee region.

Ownership category

akta.pro rank

Product category

Clinical Research Services

SIC

Services-Specialty Outpatient Facilities, Nec (8093), Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro industry

PRIMARYHLAGACAE

Clinical Trial Site Operations & Study Coordination

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Clinical Trial Services & Site Management (SMO)

Keywords

• Clinical trial services
• Pulmonary clinical research
• Clinical research site
• Phase 2 trials
• Metabolic clinical studies

Headquarters

HQ city

Franklin

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Clinical Trial Conduct Services: Revenue generated from conducting clinical trials for pharmaceutical sponsors. The company serves as a clinical research site, executing trials on behalf of sponsor organizations including AstraZeneca, GSK, Boehringer Ingelheim, and others. Compensation comes from sponsors for study conduct, patient enrollment, and data collection.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Clinical Trials Center of Middle Tennessee is a physician-led clinical research site that conducts Phase 2 and Phase 3 clinical trials on behalf of pharmaceutical sponsors across pulmonary conditions (asthma, COPD, bronchiectasis, pulmonary fibrosis) and metabolic conditions (obesity, Type II diabetes). The center executes study protocols, recruits and screens patient participants, collects clinical data, and coordinates with sponsors and participants' established physicians throughout the trial lifecycle.

Product overview

Clinical Trials Center of Middle Tennessee is a physician-led clinical research center offering a unified portfolio of Phase 1-4 clinical trial services. The company operates five core therapeutic programs: Asthma Clinical Trials (featuring the GSK Modify study), Bronchiectasis Clinical Trials (including Vento, Verona 220, and CSL787 studies), COPD Clinical Trials (with Embark, Endura, Verona 212, Presto, and Pfizer studies), Oral GLP1 Clinical Trials (featuring AstraZeneca's Embold study for obesity/diabetes), and Pulmonary Fibrosis Clinical Trials (including PURETEC 301, BI-0002, and MIST studies). These clinical research services are conducted in partnership with pharmaceutical sponsors including AstraZeneca, Boehringer Ingelheim, GSK, PureTech, United Therapeutics, Sanofi, Chiesi, and Avalyn.

Differentiator

Problem solved

Functional benefit

Products and services

• Asthma Clinical Trials Clinical trial conduct services evaluating treatments for Type 2 Asthma, including the GSK 222926 (Modify) Phase 3b/4 study examining depemokimab for exacerbation rates and clinical remission. Services are delivered to pharmaceutical sponsors and offered to qualifying patient participants.
• Bronchiectasis Clinical Trials Clinical trial conduct services for bronchiectasis conditions including non-cystic fibrosis bronchiectasis (NCFBE), featuring trials such as Vento GSK 223977, Verona 220 (ensifentrine), and CSL787. Services are delivered to pharmaceutical sponsors and offered to qualifying patient participants.
• COPD Clinical Trials Clinical trial conduct services for chronic obstructive pulmonary disease (COPD), including studies such as Embark (tezepelumab/AstraZeneca), Endura (depemokimab/GSK), Verona 212, Presto, and Pfizer C4531031. Services are delivered to pharmaceutical sponsors and offered to qualifying patient participants.
• Oral GLP1 Clinical Trials Clinical trial conduct services for obesity and Type II diabetes mellitus, featuring the Embold study (elecoglipron/AstraZeneca) evaluating GLP1 receptor agonist treatments. Services are delivered to pharmaceutical sponsors and offered to qualifying patient participants.
• Pulmonary Fibrosis Clinical Trials Clinical trial conduct services for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), including PURETEC 301 (LYT-100/Puretech), BI-0002 (Boehringer Ingelheim), and MIST (AP01/Avalyn Pharma). Services are delivered to pharmaceutical sponsors and offered to qualifying patient participants.

Quantifiable outcome

• Patient reported no cough for over a year after participating in asthma trial
• +1 more outcomes

Named customers4 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Twelve partnerships are on record, tiered core and minor.

• AstraZenecacoreStrategic or Co-development PartnerMajor pharmaceutical sponsor conducting multiple clinical trials including COPD (Embark study with tezepelumab), obesity/diabetes (Embold study with elecoglipron), and other Phase 3 trials.
• GSK (GlaxoSmithKline)coreStrategic or Co-development PartnerPharmaceutical sponsor for asthma trial (Modify with depemokimab), bronchiectasis trial (Vento with GSK3862995B), and COPD trial (Endura). Multiple Phase 2/3 studies ongoing.
• Boehringer IngelheimcoreStrategic or Co-development PartnerPharmaceutical sponsor for pulmonary fibrosis trial (BI-0002 / BI 1493-0002) evaluating BI 765423 in patients with Idiopathic Pulmonary Fibrosis.
• MerckcoreStrategic or Co-development PartnerListed as one of the pharmaceutical sponsors the company collaborates with for clinical studies.
• PureTech HealthcoreStrategic or Co-development PartnerSponsor for PURETEC 301 trial evaluating LYT-100 (Deupirfenidone) compared to pirfenidone in adults with Idiopathic Pulmonary Fibrosis.
• United TherapeuticsminorStrategic or Co-development PartnerListed as a pharmaceutical sponsor partner for clinical studies.
• SanofiminorStrategic or Co-development PartnerListed as a pharmaceutical sponsor partner for clinical studies.
• ChiesiminorStrategic or Co-development PartnerListed as a pharmaceutical sponsor partner for clinical studies.
• Avalyn PharmacoreStrategic or Co-development PartnerSponsor for MIST trial evaluating inhaled pirfenidone (AP01) for Progressive Pulmonary Fibrosis (PPF) over 52 weeks.
• Verona PharmacoreStrategic or Co-development PartnerSponsor for Verona 220 trial (NCFBE) and Verona 212 trial (COPD) evaluating ensifentrine inhalation formulations.
• CSL BehringminorStrategic or Co-development PartnerSponsor for CSL787 Phase 1 trial investigating nebulized CSL787 in subjects with Non-Cystic Fibrosis Bronchiectasis.
• PfizercoreStrategic or Co-development PartnerSponsor for C4531031 Phase 2/3 trial investigating pf-07275315 in adult participants with moderate-to-severe COPD.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• Flourish Research: Multi-site integrated clinical research organization formed from the combination of several regional SMOs (including DM Clinical Research). Comparable SMO/specialty research site model with broader therapeutic and geographic coverage than CTC.
• Velocity Clinical Research: One of the largest US site management organizations operating multi-therapeutic integrated research sites across the country. Directly comparable in business model (multi-specialty clinical trial site network) but operates at much greater scale and geographic breadth.
• Care Access Research: Decentralized and site-based clinical research provider operating at national scale. Comparable in operating clinical trial sites for major sponsors but at significantly greater geographic and operational scale.

Direct peers

• PMG Research: Multi-site clinical research organization operating as an integrated research site network across the US. Directly comparable SMO model conducting Phase 2-4 trials for major pharmaceutical sponsors.
• Wake Research: Multi-therapeutic, multi-site clinical research network headquartered in North Carolina. Comparable site-based SMO model conducting Phase 2/4 trials for major pharmaceutical sponsors.
• ObjectiveHealth: Specialty clinical research site network; notably, CTC's Clinical Research Director Erica Scaramuzza previously worked at ObjectiveHealth. Closely comparable SMO-style business model focused on partnering with physician practices to run clinical trials.
• Accel Research Sites: Network of clinical research sites across the southeastern US and beyond, conducting trials in multiple therapeutic indications. Comparable SMO-style business with similar sponsor relationships and trial mix.
• Meridien Research: Independent clinical research site network operating across multiple therapeutic areas including pulmonary, metabolic, and related indications. Directly comparable multi-site SMO model serving similar Phase 2/3 sponsor protocols.

Others

• Janssen / Johnson & Johnson Innovative Medicine Clinical Trials: Pharmaceutical sponsor running pulmonary and metabolic trials; not a competitor but an adjacent ecosystem participant that sources trials to sites like CTC. Highly relevant as a potential sponsor counterpart in the same therapeutic areas.

Regional players

• Penrose-St. Francis Clinical Research: Hospital-affiliated clinical research program in Colorado Springs conducting Phase 2/3 trials across multiple therapeutic areas including pulmonary. Comparable physician-led research site operating within a defined regional catchment.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/tn_ctc

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Clinical Trials Center